Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.6952W HIGH $34.39
Volume
3.10 M
Value Traded
69.99 M
Short % Float
33.73%
+3.16%Week
+0.13%1 Month
-16.04%3 Month
+10.44%6 Month
+80.71%5 Year
+104.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.01 B
EPS (TTM)
-0.73
P/E Ratio
-
Ent. Value
3.00 B
Total Shares
168.61 M
Float Shares
124.15 M
Insiders
26.37%
Institutions
111.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TNGX Catalyst Timeline
Dated clinical, regulatory and corporate events for Tango Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tango Therapeutics, Inc.
258Total events
2Upcoming
31Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationvopimetostatTrial
Plan to initiate Phase 3 randomized-controlled trial of vopimetostat + daraxonrasib in front-line pancreatic cancer
pancreatic cancer (first-line MTAP deleted)source ↗
◆Topline ReadoutvopimetostatClinical Data
Disclose vopimetostat lung cancer monotherapy data
lung cancersource ↗
◆Topline ReadoutTNG456Clinical Data
Release initial TNG456 glioblastoma data
glioblastoma (GBM)source ↗
●Oral PresentationvopimetostatPresentation
Present 2/3L PDAC vopimetostat + RAS(ON) inhibitors combination data at a scientific conference
pancreatic ductal adenocarcinoma (PDAC)source ↗
▼Equity OfferingCorporate
Pricing of $600 million upsized public offering of common stock and pre-funded warrants
▲Topline ReadoutvopimetostatClinical Data
Initial Phase 1/2 data for vopimetostat + daraxonrasib in PDAC: 92% ORR, 90% 6-month PFS
pancreatic ductal adenocarcinoma (PDAC)source ↗
●Oral PresentationPresentation
Investor conference call to discuss Phase 1/2 data
pancreatic ductal adenocarcinoma (PDAC)source ↗
◆Management ChangeCorporate
Appointment of Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corporate Strategy
▲Partnership / LicensevopimetostatCorporate
Clinical trial collaboration and supply agreement with Erasca for vopimetostat in combination with ERAS-0015
Pancreatic cancer and other tumor typessource ↗
◆Oral PresentationPresentation
Participation in Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat
◆Oral PresentationPresentation
Corporate presentation at 44th Annual J.P. Morgan Healthcare Conference
●Management ChangeCorporate
Barbara Weber retires as CEO, Malte Peters appointed as President and CEO
▼Program DiscontinuationTNG908DiscontinuedCorporate
Discontinuation of TNG908 clinical program
◆Oral PresentationPresentation
Fireside chat at Piper Sandler 37th Annual Healthcare Conference
◆Poster PresentationTNG260Presentation
First clinical data on TNG260 in combination with pembrolizumab at SITC 2025
STK11-mutated advanced solid tumorssource ↗
◆Poster PresentationPresentation
Inhibition of MGAT1 overcomes STK11-driven immune evasion in NSCLC
non-small cell lung cancersource ↗
◆Oral PresentationTNG260Presentation
TNG260 data presented at SITC Annual Meeting
STK11 mutant/KRAS wild type NSCLCsource ↗
▼Equity OfferingCorporate
Pricing of $210 million underwritten offering of common stock and pre-funded warrants
▲Oral PresentationvopimetostatPresentation
Positive data from ongoing Phase 1/2 study presented
MTAP-deleted cancerssource ↗
▲FDA Feedback ReceivedvopimetostatFDA Meeting
FDA alignment on go-forward dose 250 mg QD
MTAP-deleted pancreatic cancersource ↗
▲Enrollment CompletevopimetostatTrial
First dose escalation cohort fully enrolled (n=7)
MTAP-deleted/RAS mut pancreatic and lung cancer (combination with RAS(ON) inhibitors)source ↗
▲Full ResultsvopimetostatClinical Data
49% ORR and mPFS 9.1 months in histology-selective cohort
MTAP-del cancers (histology-selective cohort)source ↗
▲Orphan Drug DesignationTNG456Designation
FDA granted Orphan Drug Designation for TNG456 for malignant glioma
malignant gliomasource ↗
▲Topline ReadoutvopimetostatClinical Data
Pancreatic cancer cohort data: mPFS 7.2 months, ORR 25% in 2L
MTAP-del pancreatic cancer (2L)source ↗
▲Enrollment UpdatevopimetostatTrial
Robust enrollment in combination study with RAS(ON) inhibitors
MTAP-del pancreatic and lung cancer (2L+)source ↗
▲Enrollment CompletevopimetostatTrial
Lung cancer cohort fully enrolled (n=41)
MTAP-del lung cancersource ↗
▲FDA Feedback ReceivedvopimetostatFDA Meeting
FDA agreement on 250 mg QD go-forward dose
MTAP-del solid tumorssource ↗
◆Quarterly UpdatevopimetostatCorporate
FDA consultation on pivotal trial design scheduled later this quarter
MTAP-deleted pancreatic cancersource ↗
◆Oral PresentationPresentation
Participation in 2025 Cantor Global Healthcare Conference fireside chat
▲Enrollment MilestonevopimetostatTrial
41 patients in histology agnostic cohort enrolled as of September 1, 2025
MTAP-deleted cancers (histology agnostic cohort)source ↗
●Partnership / LicenseCorporate
Mutual agreement to truncate Gilead collaboration research term from seven to five years
◆Topline ReadoutTNG462Clinical Data
Monotherapy data expected in second half of 2025
MTAP-deleted cancers (monotherapy)source ↗
◆Topline ReadoutTNG260Clinical Data
Clinical data update on TNG260 in combination with pembrolizumab
NSCLC with STK11 loss-of-function mutationsource ↗
▲First Patient DosedTNG462Trial
First patient dosed in Phase 1/2 trial of TNG462 plus daraxonrasib or zoldonrasib
MTAP-deleted RAS mutant metastatic pancreatic or lung cancersource ↗
◆Oral PresentationPresentation
Participation in 46th Annual Goldman Sachs Global Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How TNGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | Vopimetostat (TNG462) | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$458M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 30%
Small Cap(rank 199 of 660)
Percentile Rank
Tango Therapeutics, Inc. carries a moderate pipeline score (44/100), with $705M risk-adjusted pipeline value, led by TNG462 in MTAP-deleted Solid Tumors (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TNG462 Small moleculeNCT05732831 | Locally Advanced Solid Tumor | Phase 1 | RECRUITING | 225 | Jun 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every TNGX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vopimetostat | metastatic pancreatic ductal adenocarcinoma | Phase 1/2 | 2026-06-08 | objective response rate: 92%; six month progression free survival rate: 90%Read More | Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Crystal AdamOfficer (President, R&D) | Option | 27,000 142,743 held | $5.20 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TNGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 3.7 % (32.1 %) | 434.53 M | 13.90 M | 4.51% ( 600.00 K) |
TNGX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TNGX ranks across every disease it competes in
Competitive Position is a premium feature
See how TNGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTNGX News
TNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics announced the granting of stock options and restricted stock units to a new employee under its 2023 Inducement Plan. The options are priced at $22.35 per share and will vest over time, contingent on the employee's continued employment. This initiative aims to attract talent to support the company's mission in precision medicine for cancer treatment.
Read more →TNGXTango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Tango Therapeutics, Inc. will participate in the 2026 Cantor Global Healthcare Conference on September 9, 2026. The management team will engage in a fireside chat, which will be available via live webcast. A replay will be accessible for 90 days post-event. The company is dedicated to advancing precision medicine for cancer treatment.
Read more →TNGXTango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics has reported its second quarter 2026 financial results, highlighting the continued preparation for the late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer. The company is set to present positive Phase 1/2 data from this combination study at the 2026 ESMO conference.
Read more →TNGX▼ -6.7%on this newsshared move
Tango Therapeutics Announces Executive Chair Transition
Tango Therapeutics announced the resignation of Dr. Barbara Weber as Executive Chairman. Dr. Weber expressed pride in the company's achievements and confidence in its future. Tango President Dr. Malte Peters acknowledged her contributions to the company, emphasizing the commitment to advancing precision cancer medicines.
Read more →TNGXTango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing over 30 years of biopharmaceutical experience. His expertise in oncology and corporate strategy is expected to aid Tango in advancing its investigational drug, vopimetostat, towards late-stage development for pancreatic cancer. This appointment reflects Tango's commitment to enhancing its leadership as it transitions from research to commercialization.
Read more →TNGX▼ -9.1%on this news
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Tango Therapeutics has announced the pricing of an underwritten public offering of approximately $600 million. The offering includes 18,166,667 shares of common stock priced at $30.00 each, along with pre-funded warrants. The expected closing date is June 11, 2026, pending customary conditions. The company aims to use the proceeds to advance its cancer therapeutics.
Read more →TNGX▲ +53%on this newsshared move
Tango Therapeutics Announces Proposed $500 Million Public Offering
Tango Therapeutics has announced a proposed public offering of $500 million in common stock to fund its precision cancer medicine initiatives. The offering is underwritten by J.P. Morgan and other financial institutions, with an additional option for underwriters to purchase more shares. However, the completion of the offering is contingent on market conditions.
Read more →TNGX▲ +53%on this newsshared move
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics reported promising results from its ongoing Phase 1/2 trial combining vopimetostat and daraxonrasib for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The combination achieved a 92% objective response rate and a 90% six-month progression-free survival rate. The company plans to advance this combination into Phase 3 trials, aiming to provide a chemotherapy-free treatment option for patients with MTAP-deleted pancreatic cancer.
Read more →TNGX▲ +8.6%on this news
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics has reported its financial results for the first quarter of 2026, highlighting key business developments and a strong cash position of $380 million. The company remains focused on advancing its vopimetostat candidate in pivotal studies for pancreatic cancer, with upcoming initial data expected in 2026. Recent leadership changes aim to support the late-stage clinical development of their drug candidates. However, the company reported an increased net loss compared to the previous year, attributed to a decline in collaboration revenue and expenses related to its research and development activities.
Read more →TNGX▲ +5.3%on this news
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Matthew Gall appointed Chief Financial Officer - - Additional key appointments add expertise in clinical operati
Tango Therapeutics has announced several key leadership appointments to accelerate the late-stage development of vopimetostat, a PRMT5 inhibitor targeting pancreatic cancer. Matthew Gall joins as Chief Financial Officer, with Yen-Ching Chua and Janice Kapty, PhD taking on roles in clinical operations and corporate strategy, respectively. The company's CEO highlighted the importance of these changes in driving growth and preparing for potential regulatory approval, along with a commitment to present key clinical data later this year. The leadership additions aim to enhance Tango's strategic and operational capacity as it moves towards commercialization.
Read more →TNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
Tango Therapeutics announced the grant of stock options and restricted stock units to a new employee as part of its 2023 Inducement Plan. The options, totaling 367,500 shares, have an exercise price of $11.94 per share, matching the stock's closing price on the grant date. The RSUs will vest over three years, contingent on continued employment.
Read more →TNGX▲ +36.3%on this newsshared move
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Tango Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of $343 million and ongoing robust enrollment in clinical trials for its lead product, vopimetostat. The company is set to initiate a pivotal study in 2L pancreatic cancer in 2026 and has entered a supply agreement with Erasca for further exploration of vopimetostat's potential. Despite a net loss increase, the company remains optimistic about its pipeline and strategic collaborations.
Read more →TNGXTango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Tango Therapeutics, Inc. (NASDAQ: TNGX) will announce its fourth quarter 2025 financial results on March 5, 2026, prior to the U.S. market opening. The company will not hold a conference call but will participate in three upcoming investor conferences. These events will be available via live webcast and archived for 90 days.
Read more →TNGX▲ +5.1%on this news
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Tango Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, with CEO Malte Peters scheduled for a fireside chat. The event is set for February 12, 2026, and will be available via a live webcast. The company focuses on precision medicine and synthetic lethality in cancer treatment.
Read more →TNGX▲ +6.3%on this news
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Tango Therapeutics announced the retirement of CEO Dr. Barbara Weber, who will become Executive Chair. Dr. Malte Peters, a board member since 2018, has been appointed as the new CEO. Dr. Weber praised Peters' leadership and expertise, particularly in late-stage clinical development. The company aims to continue its growth and advance its clinical pipeline under Peters' leadership.
Read more →TNGXTango Therapeutics Appoints Sung Lee to Board of Directors
Tango Therapeutics has appointed Sung Lee to its Board of Directors, enhancing its leadership team. Lee, with over 20 years of experience in finance within the biopharmaceutical sector, is expected to contribute significantly to the company's strategic goals. His background includes roles at Cytokinetics and Gilead Sciences, which will support Tango's late-stage clinical development efforts.
Read more →About Tango Therapeutics, Inc.
Headquarters201 BROOKLINE AVENUE, BOSTON, MA, 02215
BIOPHARMAWATCH ELITE PLUS
Trade the next TNGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime